Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [125]
In the citing paper
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [24]
In the citing paper
“Patient-derived organoids or tumoroids retain cellular heterogeneity and immune cells, thus are able to more strongly recapitulate a three-dimensional (3D) tumor microenvironment ex vivo compared to homogeneous cell lines (Hill et al., 2018; Kopper et al., 2019).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“Ovarian tumoroid cultures have been established from both ascitic fluid and primary tumors, to date primarily from the more common HGSOC but also from LGSOC, MOC, OCCC, and EnOC (Hill et al., 2018; De Witte et al., 2020; Nanki et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“In contrast, it has been noted that organoid propagation methods tend to be selective and result in a cell population that may not be representative of the original tumor heterogeneity and in turn, treatment response, particularly in patients who have undergone previous neoadjuvant therapy (Hill et al., 2018).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 2×
“2 and Table 1), because olaparib sensitivity is a useful surrogate marker for an HR defect (7).”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultWhole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 2×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Cited by
Items 201–300 of 457
Functional profiling of nucleotide Excision repair in breast cancer
Rajkumar-Calkins, A., Szalat, R. E., Dreze, M., Khan, I., Frazier, Z., Reznichenkov, E., Schnorenberg, M. R., Tsai, Y., Nguyen, H. Q., Kochupurakkal, B. S., et al. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102697 · Cited by 23
“Although assays to profile DNA repair capacity in clinical breast specimens and other tumor types have been described[30, 31], challenges with tissue collection and processing as well Rajkumar-Calkins et al.”
Self-citationModelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches
Zakarya, R., Howell, V. M., & Colvin, E. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134806 · Cited by 25
“Another promising feature of organoids includes the ability to form human microtissues from primary cancer cells [84].”
BackgroundExploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer
Singh, T., Neal, A. S., Moatamed, N. A., & Memarzadeh, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010305 · Cited by 24
“One short-term patient-derived tumor organoid study of high grade serous ovarian cancer was reported by Hill and colleagues wherein their research group established 33 organoid lines from 22 ovarian cancer patients [72].”
BackgroundMethodPhan, Z., Ford, C. E., & Caldon, C. E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106927 · Cited by 19
Alsaadi, A., Artibani, M., Hu, Z., Wietek, N. C., Morotti, M., González, L. S., Alazzam, M., Jiang, J., Abdul, B., majd, H. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113354 · Cited by 22
Hu, H., Sun, C., Chen, J., & Li, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05654-0 · Cited by 21
“This approach allows for a wider clinical treatment window and avoids accumulating genetic background alterations as proven by an experiment (Hill et al. 2018) conducting whole-exome sequencing analysis of OC PDOs within their first two passages.”
BackgroundTonon, G., Mauceri, M., Cavarzerani, E., Piccolo, R., Santo, C. I., Demitri, N., Orian, L., Nogara, P. A., da Rocha, J. B. T., Canzonieri, V., et al. (2024) · Dalton Transactions · doi:10.1039/d4dt00919c · Cited by 22
Grobben, Y., de Man, J., van Doornmalen, A. M., Müller, M., Willemsen‐Seegers, N., Vu‐Pham, D., Mulder, W. R., Prinsen, M. B. W., de Wit, J., Sterrenburg, J. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609490 · Cited by 21
“The use of cells from ascites has a major advantage over the use of surgical biopsies or organoid cultures (40).”
BackgroundTatin, X., Muggiolu, G., Sauvaigo, S., & Breton, J. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108388 · Cited by 21
PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
von Werdt, A., Brandt, L. P., Schärer, O. D., & Rubin, M. A. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00152 · Cited by 23
“The reduction or downregulation of PARP1 combined with the restoration of BRCA activity can lead to PARPi resistance.29 In vitro experiments showed that increased parylation seemed to restore PARP function by inactivating a component of the PARP mechanism, PARG in the presence of PARPi.29 Finally, pharmacologic resist…”
BackgroundInfluentialMendoza-Martinez, A. K., Loessner, D., Mata, Á., & Azevedo, H. S. (2021) · Cancers · doi:10.3390/cancers13225745 · Cited by 21
“Tumor-derived organoids have been used in cancer research for drug screening as an alternative to explore genetic alterations that cause therapy resistance [98,99].”
Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy
Zitter, R., Chugh, R. M., & Saha, S. (2022) · Cancers · doi:10.3390/cancers14123006 · Cited by 20
“The importance of the parallel PDO model as a preliminary study of therapeutic response is highlighted in ovarian cancer organoids [98].”
BackgroundChan, W. S., Mo, X.-T., Ip, P. P. C., & Tse, K. Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6521 · Cited by 23
“9,49,55,56,68,103 However, these were limited to small case series without proper sample size calculation.”
BackgroundInfluentialAddressing Key Questions in Organoid Models: Who, Where, How, and Why?
Gómez‐Álvarez, M., Agustina‐Hernández, M., Francés‐Herrero, E., Rodríguez‐Eguren, A., Bueno-Fernández, C., & Cervelló, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242116014 · Cited by 20
Mai, S., & Inkielewicz‐Stępniak, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021066 · Cited by 21
“Efficient protocols for the culture of breast cancer (BC) organoids that are established from mammary epithelium serve as a representative collection of well-characterized BC organoids for BC research and drug discovery [69].”
BackgroundHeredia-Soto, V., López‐Guerrero, J. A., Redondo, A., & Mendiola, M. (2020) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2019.11.003 · Cited by 22
“To date, this seems a very interesting approach for OC research [65,66].”
BackgroundBanerjee, A. T., Cai, S., Xie, G., Li, N., Bai, X., Lavudi, K., Wang, K., Zhang, X., Zhang, J., Patnaik, S., et al. (2022) · Cancers · doi:10.3390/cancers14092311 · Cited by 17
Biomarkers of drug resistance in ovarian cancer – an update
Davidson, B. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1618187 · Cited by 19
Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer
Tsogas, F. K., Majerczyk, D., & Hart, P. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020867 · Cited by 18
“While technically challenging, this could be accomplished through the chronic pretreatment of in vivo animal models prior to engraftment, or in vitro by utilizing continuous peristaltic systems for reliably consistent drug delivery coupled with recently developed organoid cultures that incorporate immune cells, as wel…”
BackgroundZhang, X., Huang, P., Wang, L., Chen, S., Basappa, B., Zhu, T., Lobie, P. E., & Pandey, V. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04982-8 · Cited by 19
“Combined NPB-PARPi treatment suppresses the growth of PDECOs in ex vivo culture We next established PDECOs from the resected specimens of primary PTEN-deficient endometrioid EC as described in SI11 [57].”
MethodInfluentialHoarau-Véchot, J., Blot-Dupin, M., Pauly, L., Touboul, C., Rafii, S., Rafii, A., & Pasquier, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214173 · Cited by 16
Trillsch, F., Czogalla, B., Kraus, F. B. T., Burges, A., Mahner, S., & Kessler, M. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102484 · Cited by 18
Copper nitroprusside: An innovative approach for targeted cancer therapy via ROS modulation
Asif, K., Adeel, M., Rahman, M. M., Bartoletti, M., Kranjc, S., Čemažar, M., Canzonieri, V., Rizzolio, F., & Caligiuri, I. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116017 · Cited by 16
Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01397-1 · Cited by 19
“All PDOs were reported to harbor TP53 mutations similar to the parent tumor [27].”
BackgroundMethodInfluentialSelf-citationSelf-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH)2 NS) for Ovarian Cancer Therapy
Adeel, M., Parisi, S., Mauceri, M., Asif, K., Bartoletti, M., Puglisi, F., Caligiuri, I., Rahman, M. M., Canzonieri, V., & Rizzolio, F. (2021) · ACS Omega · doi:10.1021/acsomega.1c03010 · Cited by 17
Estermann, M., Coelho, R., Jacob, F., Huang, Y., Liang, C.-Y., Faia-Torres, A. B., Septiadi, D., Drašler, B., Karakoçak, B. B., Dijkhoff, I. M., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.121996 · Cited by 16
Zhao, H., Cheng, Y., Li, J., Zhou, J., Yang, H., Feng, Y., Yu, F., Khutsishvili, D., Wang, Z., Jiang, S., et al. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.05.018 · Cited by 19
“Prediction of personalized responses toward chemora-diation [6] and DNA repair inhibitors [7] have also been reported with high accuracy.”
Hu, C., Nagaraj, A. B., Shimelis, H., Montalban, G., Lee, K. Y., Huang, H., Lumby, C. A., Na, J., Susswein, L. R., Roberts, M. E., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2319 · Cited by 16
“RAD51C-deficient ovarian cancer patient-derived xenograft (PDX) and organoid models are known to exhibit sensitivity to PARP inhibition in vivo and ex vivo, respectively (52).”
BackgroundOvarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Fashemi, B., van Biljon, L., Rodriguez, J., Graham, O., Mullen, M., & Khabele, D. (2023) · Journal of Visualized Experiments · doi:10.3791/65068 · Cited by 16
Huffman, B. M., Feng, H., Parmar, K., Wang, J., Kapner, K. S., Kochupurakkal, B. S., Martignetti, D. B., Sadatrezaei, G., Abrams, T. A., Biller, L. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2005 · Cited by 17
Self-citationBulanova, D. R., Akimov, Y. A., Senkowski, W., Oikkonen, J., Gall-Mas, L., Timonen, S., Elmadani, M., Hynninen, J., Hautaniemi, S., Aittokallio, T. A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj1564 · Cited by 16
“The tumor-derived organoids usually recapitulate the clinical responses of the tumor of origin ( 51 , 53 , 54 , 77 ), and the effect of CK2 inhibition on RB1-deficient organoids suggests that the respective tumors could have shown sensitivity as well.”
BackgroundExploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
Gentles, L., Goranov, B., Matheson, E. C., Herriott, A., Kaufmann, A., Hall, S., Mukhopadhyay, A., Drew, Y., Curtin, N. J., & O'Donnell, R. L. (2019) · Cancers · doi:10.3390/cancers11030354 · Cited by 15
“Recent studies using the ability to form RAD51 foci in ovarian cancer organoids confirms that this assay is predictive of response to PARPi [50].”
BackgroundGao, Y., Zhou, R., Huang, J., Hu, B., Cheng, J., Huang, X., Wang, P., Peng, H.-X., Guo, W., Zhou, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704042 · Cited by 15
“once per week); (5) sorafenib group received sorafenib (30 mg/kg orally, once per day); (6) lenvatinib group received lenvatinib (30 mg/kg, orally, once per day); (7) alpelisib group received alpelisib (50 mg/kg, orally, once per day); (8) abemaciclib group received abemaciclib (50 mg/kg, orally, once per day); (9) co…”
BackgroundCleary, J. M., Wolpin, B. M., Dougan, S. K., Raghavan, S., Singh, H., Huffman, B. M., Sethi, N. S., Nowak, J. A., Shapiro, G. I., Aguirre, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1367 · Cited by 18
“The most widely utilized biomarker of replicative stress is pRPA (60, 113, 139).”
BackgroundSelf-citationPeng, K., Su, J., Xie, Z., Wang, H., Fang, M., Li, W., Chen, Y., Guan, X., Su, J., Yan, H., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14429 · Cited by 20
Patient-derived organoids as a model for tumor research
Wang, J., Feng, X., Li, Z., Chen, Y., & Huang, W. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.03.004 · Cited by 19
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response
Bradbury, A., Zenke, F. T., Curtin, N. J., & Drew, Y. (2022) · Cells · doi:10.3390/cells11152361 · Cited by 18
“Previous functional assessment of replication fork stability in short-term patient derived HGSOC organoids, indicated that replication fork instability is associated with increased sensitivity to berzosertib [47].”
BackgroundInsights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems
Tomas, E. J., & Shepherd, T. G. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01145-x · Cited by 18
“Other more targeted therapies could be used, including PARP-inhibitors (PARPi) for BRCA1/2 mutation carriers and the anti-angiogenic bevacizumab as maintenance therapy, but these are only for a select few patients who meet the treatment criteria [18–21].”
BackgroundInfluential3D dynamic cultures of HGSOC organoids to model innovative and standard therapies
Cavarzerani, E., Caligiuri, I., Bartoletti, M., Canzonieri, V., & Rizzolio, F. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1135374 · Cited by 17
“Specifically, on ovarian cancer organoids, two seminal papers reported that this technology could be used for the functional profiling of DNA repair, predicting responses to PARP inhibitors (Hill et al., 2018), and providing a long-term expansion of organoids.”
BackgroundThorel, L., Dolivet, É., Morice, P., Florent, R., Divoux, J., Perréard, M., Lecouflet, L., Desmartin, G., Alagama, C. M., Giffard, F., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03537-x · Cited by 16
Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids
Graham, O., Rodriguez, J., van Biljon, L., Fashemi, B., Graham, E., Fuh, K. C., Khabele, D., & Mullen, M. (2023) · Journal of Visualized Experiments · doi:10.3791/64878 · Cited by 16
Zhang, W., & Zheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1122322 · Cited by 17
“Over the past decades, several PDOs have been successfully cultured, including gastric tumors (36), breast tumors (37), bladder tumors (38), and ovarian tumors (39).”
BackgroundHomologous Recombination Deficiency Detection Algorithms: A Systematic Review
Mark, L. R., Terp, S. K., Krarup, H. B., Thomassen, M., Pedersen, I. S., & Bøgsted, M. (2023) · Cancers · doi:10.3390/cancers15235633 · Cited by 15
Precision preclinical modeling to advance cancer treatment
Gutmann, D. H., Boehm, J. S., Karlsson, E. K., Padron, E., Seshadri, M., WALLIS, D. E., & Snyder, J. C. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae249 · Cited by 16
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
D’Ambrosio, C., Erriquez, J., Arigoni, M., Capellero, S., Mittica, G., Ghisoni, E., Borella, F., Katsaros, D., Privitera, S., Ribotta, M., et al. (2020) · Cells · doi:10.3390/cells9020442 · Cited by 17
“Short-term monolayer cultures [46] and organoids [47] derived from patients’ biopsies have been shown as a valuable model for rapid drug testing and thus for co-clinical trials, but their application may be limited by the modest take and throughput, respectively.”
BackgroundHeinze, K., Rengsberger, M., Gajda, M. R., Jansen, L., Osmers, L., Oliveira‐Ferrer, L., Schmalfeldt, B., Dürst, M., Häfner, N., & Runnebaum, I. B. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01006-8 · Cited by 15
Ma, X., Xue, F., Pei, Z., & Zhao, Y. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114656 · Cited by 16
Cancer patient-derived organoids: Novel models for the study of natural products
Liu, S., Zhang, R., Liu, Y., Lin, X., & Chen, J. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.114373 · Cited by 16
Wang, H., Wang, L., Zhu, X., He, M., Zhong, L., Lv, Y., Li, Q., Jiang, Q., Zhang, C., Liu, X., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07112-y · Cited by 17
“Sarah J. Hill et al. showed that HR and replication fork protection defects in HGSC organoids correlated with PARPi sensitivity, regardless of DNA repair gene mutations [39].”
Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research
Clark, J., Fotopoulou, C., Cunnea, P., & Krell, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837233 · Cited by 17
Nelson, L., Barnes, B. M., Tighe, A., Littler, S., Coulson‐Gilmer, C., Golder, A., Desai, S. N., Morgan, R. D., McGrail, J. C., & Taylor, S. S. (2023) · Chromosome Research · doi:10.1007/s10577-023-09731-x · Cited by 15
“However, if grossly visible tumour material is present and/or tumour-rich regions can be isolated by microdissection, ex vivo cultures can be developed even following neoadjuvant chemotherapy (Hill et al. 2018).”
BackgroundInfluentialWang, J., Sui, Z., Huang, W., Yu, Z., & Guo, L. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.04.035 · Cited by 27
“In recent years, various approaches have been reported for generating PDTO models of different solid tumors, such as colorectal [10,11], lung [1,5], pancreatic [12,13], ovarian [14], prostate [15], breast [6,16,17], and gastric cancers [18].”
BackgroundSelf-targeted nanosystem for enhanced chemodynamic cancer therapy
Asif, K., Rahman, M. M., Canzonieri, V., Caligiuri, I., Rizzolio, F., & Adeel, M. (2025) · Biomaterials Science · doi:10.1039/d4bm01683a · Cited by 13
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
den Ouden, J. E., Zaman, G. J. R., Dylus, J., van Doornmalen, A. M., Mulder, W. R., Grobben, Y., van Riel, W. E., de Hullu, J. A., Buijsman, R. C., & van Altena, A. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27827 · Cited by 14
“Furthermore, in vitro proliferation assays in 2D cell cultures have a major advantage over proliferation assays in 3D or organoid cultures [18], which take much longer and are technically more challenging.”
BackgroundFuture Match Making: When Pediatric Oncology Meets Organoid Technology
Barbet, V., & Broutier, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674219 · Cited by 19
The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition
Mattiello, L., Rehim, S. S. A., Musella, M., Sistigu, A., Guarracino, A., Vitale, S., Corradi, F., Galassi, C., Sperati, F., Manic, G., et al. (2021) · Cancers · doi:10.3390/cancers13081957 · Cited by 15
“The ATR-CHK1 axis is particularly relevant for the survival of CSCs, which often display high levels of replication stress, and, accordingly, ATR and CHK1 inhibitors are being explored for the design of anti-CSC therapies [20,22,23].”
BackgroundLi, J., Zhang, L., Shang, Y., Liu, J., & Zhao, H. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70586 · Cited by 17
Self-citationLi, L., Kolinjivadi, A. M., Ong, K. H., Young, D. M., Marini, G. P. L., Chan, S. H., Chong, S. T., Chew, E. L., Lu, H., Golé, L., et al. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac533 · Cited by 12
Ito, Y., Kondo, J., Masuda, M., Matsuzaki, S., Onuma, K., Kanda, M., Watanabe, Y., Sakaguchi, H., Yoshino, K., Ueda, Y., et al. (2022) · Human Cell · doi:10.1007/s13577-022-00827-w · Cited by 14
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma
Matoba, Y., Zarrella, D. T., Pooladanda, V., Azimi, M., Kim, E., Kumar, S., Xu, M., Qin, X., Ray, L. J., Devins, K. M., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02621-x · Cited by 12
“The PDOs were maintained as previously described [24].”
Self-citationKim, Y., Kim, K., Joung, J., Kim, S. W., Kim, S., Lee, J.-Y., & Park, E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1351778 · Cited by 15
Bortolamiol, E., Mauceri, M., Piccolo, R., Cavarzerani, E., Demitri, N., Donati, C., Gandin, V., Kranjc, S., Kamenšek, U., Čemažar, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01203 · Cited by 14
Advances and challenges in the origin and evolution of ovarian cancer organoids
Zhang, M., Yin, R., & Li, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429141 · Cited by 15
Li, J., Gu, A., Tang, N., Li, M., & Liu, Y. (2025) · Journal of Future Foods · doi:10.1016/j.jfutfo.2024.10.009 · Cited by 15
Battistini, C., & Cavallaro, U. (2023) · Cancers · doi:10.3390/cancers15020368 · Cited by 15
“Moreover, the authors demonstrated that sensitivity to carboplatin, prexasertib, VE-822, and gemcitabine was associated with replication fork instability, while carboplatin resistance correlated with fork stability [34].”
BackgroundRago, V., Perri, A., & Agostino, S. D. (2023) · Biomedicines · doi:10.3390/biomedicines11102743 · Cited by 13
“These innovative experimental platforms involving the use of PDOs to enable the optimization of multi-drug combination therapy tailored to individual patients are widespread in clinical trials of CRC, lung cancer, and ovarian cancer [97–99].”
MethodEvangelisti, G., Barra, F., Moioli, M., Sala, P., Stigliani, S., Gustavino, C., Costantini, S., & Ferrero, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1783238 · Cited by 13
Dickson, K.-A., Xie, T., Evenhuis, C., Ma, Y., & Marsh, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168506 · Cited by 11
“The routine incorporation of organoids generated from primary tumours or PDx models into the clinical management of patients would assist in streamlining the choice of PARPi that would best suit particular cases [49,50].”
MethodExploring tumor organoids for cancer treatment
Jin, H., Yang, Q., Yang, J., Wang, F., Feng, J., Lei, L., & Dai, M. (2024) · APL Materials · doi:10.1063/5.0216185 · Cited by 12
Targeted Cancer Therapy‐on‐A‐Chip
Abed, H., Radha, R., Anjum, S., Paul, V., AlSawaftah, N., Pitt, W. G., Ashammakhi, N. A., & Husseini, G. A. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400833 · Cited by 13
Exploration of organoids in ovarian cancer: From basic research to clinical translation
Li, S., Lei, N., Chen, M., Guo, R., Han, L., Qiu, L., Wu, F., Jiang, S., Tong, N., Wang, K., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102130 · Cited by 13
Chang, Y., Wu, K., Wang, K., & Ding, D. (2024) · Cell Transplantation · doi:10.1177/09636897241281869 · Cited by 14
Predicting Response to Anthracyclines in Ovarian Cancer
Ferrero, A., Borghese, M., Restaino, S., Puppo, A., Vizzielli, G., & Biglia, N. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074260 · Cited by 13
Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas
Arias-Diaz, A. E., Ferreiro-Pantín, M., Barbazán, J., Pérez-Béliz, E., Bañobre, J. R., Casas‐Arozamena, C., Muinelo‐Romay, L., López‐López, R., Vilar, A., Curiel, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713208 · Cited by 14
“Seminal work on the generation and characterisation of PDOs in ovarian cancer has already explored their use in the screening of response to the gold standard platinum-based therapy [23] or their sensitivity to PARP inhibitors based on their DNA repair profiling [24].”
BackgroundBouberhan, S., Philp, L., Hill, S. J., Al-Alem, L., & Rueda, B. R. (2020) · Cancers · doi:10.3390/cancers12051206 · Cited by 14
Self-citationQin, X., Presser, A. G., Johnson, L., Matoba, Y., Shay, B., Xu, W., Choiniere, J., Fraser, C., Garbicz, F., Spetz, J. K. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661170 · Cited by 16
“Patient-derived organoids (PDOs) provide a platform for assessment of tumor cell sensitivity to therapy in tumor cells grown as spheroids, which more accurately reflects the morphology of patient tumors and can be more predictive of in vivo therapy efficacy 44 .”
Self-citationBoussommier-Calleja, A. (2020) · Bioengineering Innovative Solutions for Cancer · doi:10.1016/b978-0-12-813886-1.00013-9 · Cited by 10
Patient-derived organoids in ovarian cancer: Current research and its clinical relevance
Kumar, S., Raina, M., Tankay, K., & Ingle, G. M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115589 · Cited by 12
Three Dimensional Models of Endocrine Organs and Target Tissues Regulated by the Endocrine System
Luca, E., Zitzmann, K., Bornstein, S. R., Kugelmeier, P., Beuschlein, F., Nölting, S., & Hantel, C. (2023) · Cancers · doi:10.3390/cancers15184601 · Cited by 12
“Whole-genome sequencing and histology assessments indicate that PDOs from ovarian cancers mirror the features of parental tumors in addition to sharing similarities in response to chemotherapy treatments [38,163,176–178].”
Xu, Q., Wen, Y., Huang, T., Li, H., Liu, X., Shi, S.-N., Gong, W., Mills, G. B., Ma, D., Gao, Q., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00814-x · Cited by 12
“In preclinical models and patient samples of ovarian and breast cancer, including ascite metastases and in situ carcinomas, reduced DNA dam-age-induced nuclear RAD51 is positively associated with BRCA1 or BRCA2 gene defects and patient response to PARPi [65, 66].”
DNA repair pathways in ovarian cancer: Implications for therapy and resistance
Miras, I., Gutiérrez, I. V., Estévez-García, P., & Muñoz-Galván, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118719 · Cited by 12
Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 12
“Several studies utilizing cell lines, PDXs, and organoids confirm that targeting the ATR-CHK1–CDC25A/C pathway overcomes acquired PARPi resistance in BRCA1/2 m tumors [261, 311–314].”
InfluentialSelf-citationPatient-Derived In Vitro and In Vivo Models of Cancer
Claridge, S. E., Cavallo, J., & Hopkins, B. D. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-91836-1_12 · Cited by 11
Extracellular Matrix Modulates Outgrowth Dynamics in Ovarian Cancer
Alshehri, S., Pavlovič, T., Farsinejad, S., Behboodi, P., Li, Q., Centeno, D., Kung, D., Rezler, M., Lee, W., Jasiński, P., et al. (2022) · Advanced Biology · doi:10.1002/adbi.202200197 · Cited by 14
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Bouberhan, S., Bar‐Peled, L., Matoba, Y., Mazina, V., Philp, L., & Rueda, B. R. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.146 · Cited by 11
Organoids: approaches and utility in cancer research
Zhou, B., Feng, Z., Xu, J., & Xie, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002477 · Cited by 16
Chen, W., Fang, P.-H., Zheng, B., Liang, Y., Mao, Y., Jiang, X., & Tang, Q.-L. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s405010 · Cited by 12
Enhanced activity of a pluronic F127 formulated Pin1 inhibitor for ovarian cancer therapy
Saorin, G., Mauceri, M., Cavarzerani, E., Caligiuri, I., Bononi, G., Granchi, C., Bartoletti, M., Perin, T., Tuccinardi, T., Canzonieri, V., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104718 · Cited by 10
Zhang, Y., Huo, J., Yu, S., Feng, W., Tuersun, A., Chen, F., Lv, Z., Liu, W., Zhao, J., Xu, Z., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115585 · Cited by 11
Jia, Y., Wang, M., Sang, X., Liu, P., Gao, J., Jiang, K., & Cheng, H.-L. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.812264 · Cited by 10
Golder, A., Nelson, L., Tighe, A., Barnes, B. M., Coulson‐Gilmer, C., Morgan, R. D., McGrail, J. C., & Taylor, S. S. (2022) · NAR Cancer · doi:10.1093/narcan/zcac036 · Cited by 12
“Moreover, if the vast majority of HGSOC are sensitive to MLD RSR inhibition due to the high prevalence of replication stress (23,24), the search for a relevant biomarker may be simplified or even bypassed.”
BackgroundMethodInfluentialOrganoid modeling meets cancers of female reproductive tract
Li, J., Zhou, M., Xie, J. H., Chen, J., Yang, M., Ye, C., Cheng, S., Liu, M., Li, R., & Tan, R. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02186-x · Cited by 9
“…and high success rate HGSOC organoid platform, it proved that organoids ’ sensitivity to PARPi was only related to HR dysfunction but not DNA repair gene mutation status, while the sensitivity to paraplatin, CHK1, and ATR inhibitors related to replication fork protection de fi ciency [119].”
BackgroundVasiliadou, I., Cattaneo, C., Chan, P. Y. K., Henley‐Smith, R., Gregson-Williams, H., Collins, L., Wojewodka, G., Urbano, T. G., Jeannon, J., Connor, S. E. J., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084176 · Cited by 8
“Nowadays, long-term tumour organoid cultures have been established from a wide range of human epithelial tissues, including colon, 16 liver, 17 oesophagus, 16 18 stomach, 19 20 pancreas, 21 22 lung, 23 breast, 24 prostate, 25 26 bladder, 27 28 ovary 29 30 and endometrium.”
Female Reproductive Tract Organoids: Applications from Physiology to Pathology
Wang, X., Yang, D., & Peng, H. (2025) · Biomolecules · doi:10.3390/biom15070925 · Cited by 11
“The organoids derived from the surface epithelial cells of the ovary can simulate the progression and metastasis of HGSOC in in vitro experiments, lending support to this origin hypothesis [229].”
Integration of Genomic Profiling and Organoid Development in Precision Oncology
Yoon, H., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010216 · Cited by 11
Rein, H. L., & Bernstein, K. A. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103563 · Cited by 10
Next-Generation Modeling of Cancer Using Organoids
Love, J. R., & Karthaus, W. R. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041380 · Cited by 10
Wang, L., Zhang, X., Chen, S., Ye, Q., Basappa, B., Zhu, T., Lobie, P. E., & Pandey, V. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102103 · Cited by 8
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine
Lee, C.-J., Nam, Y., Rim, Y. A., & Ju, J. H. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04906-9 · Cited by 8
“Ovarian cancer organoids classified by homologous recombination deficiency (HRD) predict response to PARP inhibitors such as Olaparib with > 80% ex vivo–to–clinical concordance, demonstrating the predictive validity of phenotype-driven platforms [81].”
Development and validation of deep learning for predicting the growth of ovarian cancer organoids
Wu, H., Ma, L., Wang, L., Zhu, X., Luo, X., Zhang, C., Ha, C., Dang, Y. M., Wang, H., & Zou, D. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003575 · Cited by 10
“[5] However, there are still many limitations in orga-noid-guided precision medicine.”
Metadata
- Authors
- Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- ORCID
- Hill, Sarah J.
- Decker, Brennan
- Roberts, Emma A.
- Horowitz, Neil S.
- Worley, Michael J.
- Feltmate, Colleen M.
- Nucci, Marisa R.
- Swisher, Elizabeth M.
- Nguyen, Huy
- Yang, Chunyu
- Morizane, Ryuji
- Kochupurakkal, Bose S.
- Do, Khanh T.
- Konstantinopoulos, Panagiotis A.
- Liu, Joyce F.
- Bonventre, Joseph V.
- Matulonis, Ursula A.
- Shapiro, Geoffrey I.
- Berkowitz, Ross S.
- Crum, Christopher P.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1404-1421
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6365285
- OpenAlex
- W2891058330
- Cited by
- 452
- References
- 49
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
- U.S. Department of Defense (DOD) (BC151331P1)
- Leukemia and Lymphoma Society (LLS) (6237-13)
- Breast Cancer Research Foundation (BCRF)
- Richard and Susan Smith Family Foundation
- The Bridge Project
- HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
- MeSH terms
- Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.